NASDAQ: PSTV - Plus Therapeutics, Inc.

Altı ay boyunca karlılık: -51.99%
Temettü getirisi: 0.00%
Sektör: Healthcare

Promosyon programı Plus Therapeutics, Inc.


Şirket hakkında Plus Therapeutics, Inc.

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.

daha fazla ayrıntı
The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

IPO date 2000-11-16
ISIN US72941H4002
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://plustherapeutics.com
Цена ао 0.76
Günlük fiyat değişimi: +6.62% (0.68)
Haftalık fiyat değişimi: -39.58% (1.2)
Aylık fiyat değişimi: -39.58% (1.2)
3 ayda fiyat değişimi: -43.36% (1.28)
Altı ayda fiyat değişimi: -51.99% (1.51)
Yıllık fiyat değişimi: -63.57% (1.99)
3 yılda fiyat değişimi: -28.22% (1.01)
5 yılda fiyat değişimi: -67.19% (2.21)
10 yılda fiyat değişimi: 0% (0.725)
Yılbaşından bu yana fiyat değişimi: -32.87% (1.08)

Hafife alma

İsim Anlam Seviye
P/S 1.22 9
P/BV -4.45 0
P/E 0 0
EV/EBITDA -0.1293 0
Toplam: 4.88

Yeterlik

İsim Anlam Seviye
ROA, % -116.93 0
ROE, % 987.83 10
Toplam: 3.33

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0

Görev

İsim Anlam Seviye
Debt/EBITDA -0.3325 10
Toplam: 10

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % 63.77 8
karlılık Ebitda, % 370.11 10
karlılık EPS, % -96.93 0
Toplam: 5.8



Süpervizör İş unvanı Ödeme Doğum yılı
Dr. Marc H. Hedrick M.B.A., M.D. President, CEO & Director 945.34k 1963 (62 yıl)
Mr. Andrew J. Sims CPA VP of Finance & CFO 498.51k 1973 (52 yıl)
Ms. Desiree Smith Corporate Controller, Principal Financial & Accounting Officer N/A 1964 (61 yıl)
Dr. John K. Fraser Chief Scientist N/A 1961 (64 yıl)

Adres: United States, Austin. TX, 4200 Marathon Boulevard - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://plustherapeutics.com